Last reviewed · How we verify
Short course MDR-TB treatment regimen
At a glance
| Generic name | Short course MDR-TB treatment regimen |
|---|---|
| Also known as | Bangladesh protocol, Shortened course MDR-TB treatment, 9-month MDR-TB regimen |
| Sponsor | Medecins Sans Frontieres, Netherlands |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
- Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) (PHASE2)
- A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis
- A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China (PHASE4)
- Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (PHASE2, PHASE3)
- Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou (NA)
- Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: